ArticleJournal of translational medicine2025

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab.

Ziping Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.